Basic & Clinical Medicine ›› 2014, Vol. 34 ›› Issue (4): 464-469.

Previous Articles     Next Articles

Exenatide Treatment Improves Nonalcoholic Fatty Liver Phenotype by Regulation of PPARα and ACOX1


  • Received:2013-09-02 Revised:2013-10-24 Online:2014-04-05 Published:2014-03-31

Abstract: Objective To observe the Exenatide effect on fat-induced nonalcoholic fatty liver disease (NAFLD) in rat. Methods 120 SD rats were randomly divided into control group( CON), model group(HFD), Exenatide low, medium, high dose group ( ELD, EMD, EHD) and polyene phosphatidylcholine treatment group (PDC), each group was 20. After successfully established NAFLD, given appropriate treatment, half of the rats were sacrificed after 4 and 8 weeks. HE staining of liver slices, the corresponding detection kit liver function, blood lipids function, RT-PCR and western blot measured PPARα and ACOX1 expression. Results After 8 weeks of treatment, rat liver HE staining PDC, EMD and EHD have not any fat particles infiltration; after 4 weeks treatment, liver function AST, ALT and CHE, serum lipids CHOL and TG compared with HFD group, PDC, ELD, EMD and EHD, p <0.05,8 weeks further reduced; liver Peroxisome Proliferator-Activated Receptor α (PPARα) and Acyl Coenzyme A Oxidase 1(ACOX1) expression has also undergone a significant improvement. Conclusion Exenatide improves NAFLD Phenotype by regulation of PPARα and ACOX1 expression.

Key words: exenatide, non-alcoholic fatty liver disease, peroxisome proliferator activated receptors α, acyl coenzyme a oxidase 1